Scheduled for September 14–16, 2026, the H.C. Wainwright 28th Annual Global Investment Conference will take place at the Lotte New York Palace Hotel in New York City.
Company executives to hold investor meetings, showcasing PH-762 advancements and forthcoming development strategies
Phio Pharmaceuticals Corp. (NASDAQ: PHIO)
KING OF PRUSSIA, PA, UNITED STATES, September 12, 2026 /EINPresswire.com/ — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology firm creating therapies using its proprietary INTASYL® siRNA gene-silencing technology aimed at eliminating cancer, announced today that members of its management team will be available for one‑on‑one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.
Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. An in‑depth company profile can be found at: https://b2idigital.com/phio-pharmaceuticals
Robert Bitterman, President and Chief Executive Officer, and Lisa Carson, Chief Financial Officer, will be accessible for investor meetings throughout the conference. During the event, management will discuss the company’s lead clinical candidate PH‑762, strategic priorities, and upcoming initiatives intended to support continued execution and long‑term value creation.
Phio Pharmaceuticals’ Presentation:
An online webcast of the Phio Pharmaceuticals presentation can be accessed via this link: Journey
Conference Details:
Event: H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14-16, 2026
Location: Lotte New York Palace Hotel, New York, NY
About Phio Pharmaceuticals Corporation:
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical‑stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology with the goal of eliminating cancer. The company’s INTASYL compounds are designed to boost the body’s immune cells, enabling them to kill cancer cells more effectively. Phio’s lead clinical development program involves an
